These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37607920)

  • 1. Favorable outcomes of NPM1
    Khan I; Kaempf A; Raghuwanshi S; Chesnokov M; Zhang X; Wang Z; Domling A; Tyner JW; Camacho C; Gartel AL
    Blood Cancer J; 2023 Aug; 13(1):128. PubMed ID: 37607920
    [No Abstract]   [Full Text] [Related]  

  • 2. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear FOXM1 drives chemoresistance in AML.
    Khan I; Halasi M; Zia MF; Gann P; Gaitonde S; Mahmud N; Gartel AL
    Leukemia; 2017 Jan; 31(1):251-255. PubMed ID: 27694928
    [No Abstract]   [Full Text] [Related]  

  • 5. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells.
    Zhang JR; Lu F; Lu T; Dong WH; Li P; Liu N; Ma DX; Ji CY
    J Mol Med (Berl); 2014 Dec; 92(12):1319-30. PubMed ID: 25179295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors.
    Nestal de Moraes G; Castro CP; Salustiano EJ; Dumas ML; Costas F; Lam EW; Costa PR; Maia RC
    Int J Oncol; 2014 Nov; 45(5):1949-58. PubMed ID: 25174716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
    Kassem NM; Medhat N; Kassem HA; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
    Daver N; Liu Dumlao T; Ravandi F; Pierce S; Borthakur G; Pemmaraju N; Nazha A; Faderl S; Jabbour E; Garcia-Manero G; Cortes J; Kantarjian H; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):435-40. PubMed ID: 23763915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circ-PTK2 promotes the proliferation and suppressed the apoptosis of acute myeloid leukemia cells through targeting miR-330-5p/FOXM1 axis.
    Yi L; Zhou L; Luo J; Yang Q
    Blood Cells Mol Dis; 2021 Feb; 86():102506. PubMed ID: 33126007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Simonetti G; Mengucci C; Padella A; Fonzi E; Picone G; Delpino C; Nanni J; De Tommaso R; Franchini E; Papayannidis C; Marconi G; Pazzaglia M; Perricone M; Scarpi E; Fontana MC; Bruno S; Tebaldi M; Ferrari A; Bochicchio MT; Ghelli Luserna Di Rorà A; Ghetti M; Napolitano R; Astolfi A; Baldazzi C; Guadagnuolo V; Ottaviani E; Iacobucci I; Cavo M; Castellani G; Haferlach T; Remondini D; Capozzi F; Martinelli G
    Leukemia; 2021 Oct; 35(10):2813-2826. PubMed ID: 34193978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
    Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
    J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
    Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
    Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic abnormalities in
    Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
    Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal Abnormalities and Prognosis in
    Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
    J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
    Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
    Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.